VERU - 2 Top Healthcare Stocks Defying the Bear Market
Everyone's looking for safe harbors to park their cash amid a downwardly mobile market and globally fulminating economic turmoil. To merely beat the bear market, a stock needs to do better than lose nearly 20% of its value so far in 2022. The good news is that there are plenty of portfolio-ready stocks that continue to outperform.
But to really defy the bear market, a stock should grow rather than merely fall slightly less than everything else. With that standard in mind, let's examine a couple of top healthcare stocks that are powering onward despite stormy waters.
With shares of Veru (NASDAQ: VERU) stock galloping upward by almost 102% so far this year, the market clearly has a rosy view of this biotech's future. The company has two divisions, one for its reproductive health products and one for its cancer and COVID-19 therapies. But what's really driving the stock are two products: Entadfi, which treats benign prostatic hyperplasia (BPH) and which was just launched in August; and sabizabulin, which is being evaluated to treat severe COVID-19 as well as certain types of breast and prostate cancers.
For further details see:
2 Top Healthcare Stocks Defying the Bear Market